VPAC1 receptor (Vipr1)-deficient mice exhibit ameliorated experimental autoimmune encephalomyelitis, with specific deficits in the effector stage
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
VPAC1 receptor (Vipr1)-deficient mice exhibit ameliorated experimental autoimmune encephalomyelitis, with specific deficits in the effector stage
Authors
Keywords
Multiple sclerosis, Experimental autoimmune encephalomyelitis, Neuropeptide, VPAC1, Neuroimmunomodulation
Journal
Journal of Neuroinflammation
Volume 13, Issue 1, Pages -
Publisher
Springer Nature
Online
2016-06-30
DOI
10.1186/s12974-016-0626-3
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- VPAC2 (vasoactive intestinal peptide receptor type 2) receptor deficient mice develop exacerbated experimental autoimmune encephalomyelitis with increased Th1/Th17 and reduced Th2/Treg responses
- (2015) Yossan-Var Tan et al. BRAIN BEHAVIOR AND IMMUNITY
- Role of the innate and adaptive immune responses in the course of multiple sclerosis
- (2015) Bernhard Hemmer et al. LANCET NEUROLOGY
- Vasoactive Intestinal Peptide-Deficient Mice Exhibit Reduced Pathology in Trinitrobenzene Sulfonic Acid-Induced Colitis
- (2015) Catalina Abad et al. NEUROIMMUNOMODULATION
- Using EAE to better understand principles of immune function and autoimmune pathology
- (2013) Manu Rangachari et al. JOURNAL OF AUTOIMMUNITY
- Paradoxical Effect of Cortistatin Treatment and Its Deficiency on Experimental Autoimmune Encephalomyelitis
- (2013) L. Souza-Moreira et al. JOURNAL OF IMMUNOLOGY
- VPAC1 receptor expression in peripheral blood mononuclear cells in a human endotoxemia model
- (2013) Angela Storka et al. Journal of Translational Medicine
- Vasoactive intestinal peptide increases VEGF expression to promote proliferation of brain vascular endothelial cells via the cAMP/PKA pathway after ischemic insult in vitro
- (2013) Jie Yang et al. PEPTIDES
- Pharmacology and functions of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: IUPHAR Review 1
- (2012) Anthony J Harmar et al. BRITISH JOURNAL OF PHARMACOLOGY
- Regional Neural Activation Defines a Gateway for Autoreactive T Cells to Cross the Blood-Brain Barrier
- (2012) Yasunobu Arima et al. CELL
- An autoimmunity odyssey: how autoreactive T cells infiltrate into the CNS
- (2012) Naoto Kawakami et al. IMMUNOLOGICAL REVIEWS
- VIP Deficient Mice Exhibit Resistance to Lipopolysaccharide Induced Endotoxemia with an Intrinsic Defect in Proinflammatory Cellular Responses
- (2012) Catalina Abad et al. PLoS One
- VPAC1 (vasoactive intestinal peptide (VIP) receptor type 1) G protein-coupled receptor mediation of VIP enhancement of murine experimental colitis
- (2011) Mahesh Yadav et al. CELLULAR IMMUNOLOGY
- Characterization and use of a rabbit-anti-mouse VPAC1 antibody by flow cytometry
- (2011) Rebecca J. Hermann et al. JOURNAL OF IMMUNOLOGICAL METHODS
- Characterization of Intestinal and Pancreatic Dysfunction in VPAC1-Null Mutant Mouse
- (2011) Dorit Fabricius et al. PANCREAS
- Identification of the early VIP-regulated transcriptome and its associated, interactome in resting and activated murine CD4 T cells
- (2010) Sheri Tinnell Dorsam et al. MOLECULAR IMMUNOLOGY
- Effects of PACAP and VIP on hyperglycemia-induced proliferation in murine microvascular endothelial cells
- (2010) Alessandro Castorina et al. PEPTIDES
- The Expression of Vasoactive Intestinal Peptide Receptor 1 Is Negatively Modulated by MicroRNA 525-5p
- (2010) Elisa Cocco et al. PLoS One
- Vasoactive intestinal peptide loss leads to impaired CNS parenchymal T-cell infiltration and resistance to experimental autoimmune encephalomyelitis
- (2010) C. Abad et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Toll-like receptor stimulation differentially regulates vasoactive intestinal peptide type 2 receptor in macrophages
- (2009) Juan Luis Herrera et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Postulated Role of Vasoactive Neuropeptide-Related Immunopathology of the Blood Brain Barrier and Virchow-Robin Spaces in the Aetiology of Neurological-Related Conditions
- (2009) D. R. Staines et al. MEDIATORS OF INFLAMMATION
- C-C chemokine receptor 6–regulated entry of TH-17 cells into the CNS through the choroid plexus is required for the initiation of EAE
- (2009) Andrea Reboldi et al. NATURE IMMUNOLOGY
- Pituitary Adenylate Cyclase-Activating Polypeptide and Its Receptors: 20 Years after the Discovery
- (2009) D. Vaudry et al. PHARMACOLOGICAL REVIEWS
- Pituitary adenylyl cyclase-activating polypeptide is an intrinsic regulator of Treg abundance and protects against experimental autoimmune encephalomyelitis
- (2009) Yossan-Var Tan et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Localizing central nervous system immune surveillance: Meningeal antigen-presenting cells activate T cells during experimental autoimmune encephalomyelitis
- (2008) Pia Kivisäkk et al. ANNALS OF NEUROLOGY
- PACAP38 induces migraine-like attacks in patients with migraine without aura
- (2008) Henrik Winther Schytz et al. BRAIN
- TCR signaling and environment affect vasoactive intestinal peptide receptor-1 (VPAC-1) expression in primary mouse CD4 T cells
- (2008) Emilie E. Vomhof-DeKrey et al. BRAIN BEHAVIOR AND IMMUNITY
- Stimulatory and suppressive signal transduction regulates vasoactive intestinal peptide receptor-1 (VPAC-1) in primary mouse CD4 T cells
- (2008) Emilie E. Vomhof-DeKrey et al. BRAIN BEHAVIOR AND IMMUNITY
- Vasoactive Intestinal Peptide Is Critical for Circadian Regulation of Glucocorticoids
- (2008) Dawn H. Loh et al. NEUROENDOCRINOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now